Niraparib
Category: CancerNiraparib Overview
Niraparib (trade name Zejula) is an orally active[1] small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer. Niraparib was granted fast track designation by the US Food and Drug Administration (FDA), and Tesaro submitted a new drug application in 2016.[2] It was approved on 27 March 2017 in the US,[3] and has been approved in Europe on 16 November 2017.[4] Contents 1 Medical uses 2 Contraindications 3 Side ef...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Niraparib
Recent Niraparib Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Niraparib
- Capsule: 100mg
Other drugs which contain Niraparib or a similar ingredient: (1 result)
- ZEJULA Niraparib1 discussion